联合健康向其自有的医生集团支付的费用比外部医生集团高17%。
UnitedHealth pays its own physician groups 17% more than outside ones

原始链接: https://www.statnews.com/2025/11/03/unitedhealth-pays-its-optum-physicians-17-percent-more/

一项发表在《健康事务》上的新研究证实了STAT News之前的报道,揭示联合健康集团似乎在经济上偏袒其自身的医生诊所。联合健康保险部门UnitedHealthcare,平均而言,对Optum拥有的诊所支付的常见服务费用比同一地区的独立诊所高17%。 在UnitedHealthcare拥有重要市场份额的市场中,这种差异高达61%的更高支付额。这项研究基于STAT早期的调查,表明联合健康集团可能通过将更多资金导向其关联诊所,从而规避旨在限制保险公司利润的法规。虽然联合健康集团对少数诊所的支付低于市场平均水平,但STAT之前的分析发现,对Optum诊所的支付通常是某些服务的典型费率的两倍。这引发了对公平竞争和医疗系统内潜在反竞争行为的担忧。

## 联合健康与医疗系统 frustation - 摘要 一篇Statnews文章引发了Hacker News的讨论,揭示联合健康向其医生集团支付的费用比外部医生高17%,凸显了美国医疗系统普遍存在的不满。 许多评论者表达了对高昂成本、复杂官僚主义和缺乏控制的不满。一些用户感到被困住,有些人甚至考虑离开国家或推迟创业,因为担心医疗问题。一个反复出现的主题是即使有雇主赞助的计划,也很难处理保险,并且感觉激励措施优先考虑利润而非患者福祉。 提出的解决方案包括全民医保、将医疗与就业脱钩、监管服务提供者成本以及增加医生数量。大家普遍认为目前的系统不可持续,许多人将责任归咎于保险公司*以及*以盈利为导向的医疗模式的固有复杂性。一些用户分享了与联合健康相关的负面经历,例如索赔被拒和行政障碍。
相关文章

原文

Tara Bannow covers hospitals, providers, and insurers. You can reach Tara on Signal at tarabannow.70.

UnitedHealth Group pays its own physician practices much more than it pays competing practices, a new study finds, reinforcing STAT’s own analysis on the subject and presenting fresh evidence that the conglomerate may be skirting a rule designed to curb health insurer profits. 

UnitedHealth’s insurance arm, UnitedHealthcare, pays practices under its UnitedHealth-owned Optum umbrella 17% more on average for common services than it pays non-Optum practices in the same region, according to the study, published today in Health Affairs. In areas where its insurance arm has a large market share, it pays Optum practices 61% more. 

The study’s lead author, Daniel Arnold, said his research was inspired in part by STAT’s reporting from last year, which found that UnitedHealthcare paid 13 of 16 Optum practices more than others in the same market, ranging from as little as 3% more to 111% more. UnitedHealth paid the other 3 practices less than the market average. UnitedHealth paid roughly two times the market average for some common services, STAT found.

STAT+ Exclusive Story

STAT+

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe
联系我们 contact @ memedata.com